L. Hart

发表

Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.

C. Horak, T. Lynch, S. Khambata-Ford, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours

Manish R. Patel, N. Halama, L. Hart, 2020, British journal of clinical pharmacology.

A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer

J. Berlin, M. Mulcahy, L. Hart, 2012, Clinical Cancer Research.

A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer.

L. Hart, D. Ramies, L. Fehrenbacher, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial.

D. Amadori, M. Dowsett, M. Gnant, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.

J. Berlin, A. Oza, J. Marshall, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial

A. Grothey, K. Rowland, L. Hart, 2008 .

Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT.

J. Hainsworth, A. Grothey, L. Hart, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study.

J. Hainsworth, L. Hart, B. Childs, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The duke afm program intensive induction chemotherapy for metastatic breast cancer

R. Bast, E. Shpall, L. Hart, 1990, Cancer.

Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial.

J. Hainsworth, J. Sosman, L. Hart, 2007, Clinical genitourinary cancer.

Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer.

C. Obasaju, M. Socinski, L. Hart, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tracheoesophageal (TE) fistula development in a phase II trial of concurrent chemoradiation (CRT) and bevacizumab (B) in limited-stage small-cell lung cancer (LS-SCLC)

J. Hainsworth, L. Hart, H. Burris, 2008 .

Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer

M. Gross, J. Hainsworth, L. Hart, 2014, Clinical Cancer Research.

Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.

M. Piccart, G. Hortobagyi, J. Baselga, 2013, Journal of the National Cancer Institute.

Final results of phase Ib of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).

A. Chiang, L. Hart, M. Pietanza, 2015 .

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

T. Owonikoko, P. Roberts, J. Hamm, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.

H. Koeppen, L. Hart, J. Bendell, 2017, The oncologist.

Randomized phase II study of SGN-15 (CBR96-doxorubicin immunoconjugate) with docetaxel in patients with advanced or metastatic non-small cell lung cancer (NSCLC).

C. Rudin, R. Figlin, L. Hart, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cabazitaxel Plus Lapatinib as Therapy for HER2+ Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose‐finding Study

J. Hainsworth, P. Ward, L. Hart, 2018, Clinical breast cancer.

Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.

M. Piccart, G. Hortobagyi, J. Baselga, 2013, European journal of cancer.

Inflammatory breast carcinoma. Effective multimodal approach.

L. Hart, L. Prosnitz, H. Seigler, 1987, Archives of surgery.

A randomized, placebo-controlled, phase I/II study of tivantinib (ARQ 197) in combination with cetuximab and irinotecan in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (CRC) who had received previous front-line systemic therapy.

S. Barni, L. Hart, J. Bendell, 2013 .

Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer

L. Hart, H. Burris, D. Yardley, 2013, Breast Cancer Research and Treatment.

Ridaforolimus (AP23573; MK-8669) in Combination with Trastuzumab for Patients with HER2-Positive Trastuzumab-Refractory Metastatic Breast Cancer: A Multicenter Phase 2 Clinical Trial.

B. Melichar, L. Hart, I. Ray-Coquard, 2009 .

Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial

Michael J. Morris, Howard I. Scher, Ajjai Alva, 2018, JAMA oncology.

Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial

E. Winer, R. Gelber, L. Trippa, 2022, NPJ breast cancer.

Abstract CT013: A phase Ib, open-label, multicenter study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of AZD1775 monotherapy in patients with advanced solid tumors: initial findings

Suzanne F. Jones, Melissa L. Johnson, L. Hart, 2016 .

Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab

I. Bondarenko, L. Hart, D. Spigel, 2019, Annals of Oncology.

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.

T. Owonikoko, P. Roberts, J. Hamm, 2019 .

Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma: Update of a multicenter phase II trial.

J. Hainsworth, J. Sosman, L. Hart, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies

J. Hainsworth, L. Hart, H. Hochster, 2005 .

Abstract GS1-05: TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT)

E. Winer, L. Trippa, R. Bose, 2020 .

E. Winer, Minetta C. Liu, R. Bose, 2021, Breast Cancer Research and Treatment.

Randomized phase II trial of pemetrexed with either cisplatin or carboplatin in extensive stage small cell lung cancer

C. Obasaju, M. Socinski, L. Hart, 2004 .

Small-cell lung carcinoma: an analysis of 194 consecutive patients.

J. Reeves, L. Hart, P. Blitzer, 1998, American journal of clinical oncology.

Bevacizumab, erlotinib, and imatinib in the treatment of patients (pts) with advanced renal cell carcinoma (RCC): A Minnie Pearl Cancer Research Network phase I/II trial

J. Hainsworth, J. Sosman, L. Hart, 2005 .

A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose‐expansion cohort

I. Flinn, L. Hart, E. Faber, 2021, American journal of hematology.

Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer

T. Owonikoko, P. Roberts, L. Hart, 2021, Cancer Chemotherapy and Pharmacology.

Abstract PD2-01: Randomized phase 3 trial of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor positive, node positive early breast cancer: Final efficacy and safety results of the femara versus anastrozole clinical evaluation (Face) trial

D. Amadori, M. Dowsett, M. Gnant, 2016 .

Safety, efficacy, and pharmacodynamics of the investigational agent TAK-700 in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study.

M. Gross, J. Hainsworth, L. Hart, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer

E. Winer, Zhou Zhu, P. Morris, 2020, Clinical Cancer Research.

Cystosarcoma phyllodes. Effective therapy with cisplatin and etoposide chemotherapy

L. Hart, G. Burton, K. Mccarty, 1989, Cancer.

Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2

Y. C. Heng, M. Piccart, G. Hortobagyi, 2013, Breast Cancer Research and Treatment.

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.

J. Hainsworth, L. Hart, L. Fehrenbacher, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II randomized trial of irinotecan/docetaxel (ID) or irinotecan/gemcitabine (IG) with or without celecoxib (CBX) in 2nd-line treatment of non-small-cell lung cancer (NSCLC).

M. Socinski, L. Hart, R. Lilenbaum, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II trial of irofulven (IROF)/prednisone (P), IROF/capecitabine (C)/P or mitoxantrone (M)/P in docetaxel-pretreated hormone refractory prostate cancer (HRPC) patients (pts).

J. Hainsworth, T. Ciuleanu, L. Hart, 2006, Journal of Clinical Oncology.

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

K. Flaherty, R. Kurzrock, L. Hart, 2012, The Lancet. Oncology.

Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen

L. Bosserman, M. Desilvio, L. Hart, 2012, Breast Cancer Research and Treatment.

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

E. Winer, G. Hortobagyi, K. Blackwell, 2016, The New England journal of medicine.

LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)

G. Hortobagyi, M. Campone, L. Hart, 2021, Annals of Oncology.

Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study

J. Subramanian, T. Owonikoko, L. Hart, 2020, Advances in Therapy.

TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies

Suzanne F. Jones, R. Neuwirth, L. Hart, 2017, Cancer Chemotherapy and Pharmacology.

Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: A multicentre, randomised, double‐blind, placebo‐controlled Phase II trial

I. Bondarenko, L. Hart, J. Goldschmidt, 2020, International journal of cancer.

A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy

S. Barni, L. Hart, J. Bendell, 2016, International journal of cancer.

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.

R. Herbst, L. Hart, D. Ramies, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.

F. Saad, J. Nelson, H. Scher, 2015, The Lancet. Oncology.

A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung

R. Herbst, Z. Shun, V. Miller, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.

Suzanne F. Jones, L. Hart, J. Bendell, 2014, Journal of Clinical Oncology.

Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer

L. Hart, J. Infante, R. Beckman, 2013, Cancer medicine.

Rheumatologic Evaluation of Adjuvant Letrozole in Post-Menopausal Breast Cancer Patients Discontinuing Anastrozole Due to Grade 2-3 Arthralgia – Myalgia.

S. Papish, L. Hart, G. Warsi, 2009 .

Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum- and erlotinib- resistant adenocarcinoma of the lung (NSCLA)

R. Herbst, V. Miller, L. Hart, 2007 .

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

J. Hainsworth, R. Herbst, L. Hart, 2011, The Lancet.

Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer

P. Neven, A. Bardia, F. Esteva, 2021, British Journal of Cancer.

Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients

Minetta C. Liu, A. DeMichele, M. Regan, 2021, NPJ breast cancer.

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer

P. Neven, R. Bose, H. Rugo, 2021, Breast Cancer Research and Treatment.

A phase 2 study of glembatumumab vedotin, an antibody‐drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma

Douglas B. Johnson, P. Ott, L. Hart, 2019, Cancer.

Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study.

Anand A. Dalal, G. Hortobagyi, B. Ramaswamy, 2019, Clinical breast cancer.

Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes

G. Sonpavde, D. Potvin, M. Milowsky, 2018, Cancer.

A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer.

T. Kolevska, J. von Pawel, L. Hart, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma

I. Flinn, J. Hainsworth, L. Hart, 2015, Haematologica.

Abstract 2376: Improved progression-free survival (PFS) in patients with short tumor telomere length: Subgroup analysis from a randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced NSCLC .

T. Kolevska, L. Hart, J. Schiller, 2013 .

Abstract GS4-07: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer

E. Winer, P. Morris, I. C. Tudor, 2017 .

R. Gelber, L. Trippa, Minetta C. Liu, 2022, npj Breast Cancer.

Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial

E. Winer, R. Gelber, L. Trippa, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.

C. Flowers, S. de Vos, L. Hart, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.

E. Winer, G. Hortobagyi, F. André, 2022, The New England journal of medicine.

Safety analysis of a randomized phase II trial of hedgehog pathway inhibitor (HPI) GDC-0449 versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC).

J. Berlin, L. Hart, R. Hermann, 2010 .

Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer.

M. Socinski, N. Altorki, L. Hart, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial

G. Hortobagyi, D. Cameron, L. Hart, 2017, Breast Cancer Research and Treatment.

First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 safety results.

B. Ramaswamy, K. Blackwell, J. Sparano, 2017 .

A phase I/II study of the combination of panobinostat (PAN) and carfilzomib (CFZ) in patients (pts) with relapsed or relapsed/refractory multiple myeloma (MM).

I. Flinn, L. Hart, E. Faber, 2015 .

A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma.

C. Rudin, R. Figlin, L. Hart, 2006, Lung cancer.

Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer.

J. Hainsworth, L. Hart, H. Burris, 2012, Lung cancer.

Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors

Glen J Weiss, P. LoRusso, D. V. Von Hoff, 2016, Clinical Cancer Research.

Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer.

C. Obasaju, C. Russell, L. Hart, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Bortezomib Plus Rituximab in Patients with Indolent Non-Hodgkin’s Lymphoma (NHL): A Phase 2 Study.

C. Flowers, L. Hart, S. Dakhil, 2005 .

Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer

J. Berlin, T. Ryan, H. Lenz, 2014, Investigational New Drugs.

Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC).

A. Bardia, H. Rugo, S. Loibl, 2021 .

Abstract P6-18-06: Ribociclib treatment benefit in patients with advanced breast cancer with ≥1 dose reduction: Data from the MONALEESA-2, -3, and -7 trials

P. Neven, A. Bardia, L. Hart, 2019, Poster Session Abstracts.

Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib

L. Hart, E. Santos, 2020, OncoTargets and therapy.

Phase I study of the combination of BKM120 and bevacizumab in patients with relapsed/refractory glioblastoma multiforme (GBM) or other refractory solid tumors.

J. Hainsworth, L. Hart, H. Burris, 2013 .

Metastatic hemangiopericytoma with prolonged survival

L. Hart, J. Weinberg, 1987, Cancer.

Burden of chemotherapy‐induced myelosuppression among patients with extensive‐stage small cell lung cancer: A retrospective study from community oncology practices

Trevor W. Heritage, L. Hart, K. DeYoung, 2023, Cancer medicine.

SGNLVA-001: A phase I open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer.

L. Pusztai, H. Rugo, R. Nanda, 2020 .

Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results.

A. Bardia, A. DeMichele, L. Hart, 2019, Journal of Clinical Oncology.

A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer

Suzanne F. Jones, L. Hart, J. Bendell, 2015, Investigational new drugs.

Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial

S. Verma, M. Campone, L. Hart, 2017, Breast Cancer Research and Treatment.

Abstract PD4-06: First-line ribociclib + letrozole in hormone receptor-positive, HER2-negative advanced breast cancer: Efficacy by baseline circulating tumor DNA alterations in MONALEESA-2

G. Hortobagyi, M. Campone, L. Hart, 2018 .

Correlation of GPNMB expression with outcome in breast cancer (BC) patients treated with the antibody–drug conjugate (ADC), CDX-011 (CR011-vcMMAE).

Suzanne F. Jones, L. Hart, J. Bendell, 2010 .

A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors

Suzanne F. Jones, L. Hart, J. Bendell, 2015, Cancer investigation.

A Single-Arm, Open-Label, Multi-Center Phase I/II Study Of The Combination Of Panobinostat and Carfilzomib In Patients (pts) With Relapsed Or Relapse/Refractory Multiple Myeloma (MM)

I. Flinn, L. Hart, J. Essell, 2013 .

A randomized, double-blind, phase II study of first-line FOLFOX plus bevacizumab with onartuzumab versus placebo in patients with metastatic colorectal cancer (mCRC).

L. Hart, J. Bendell, D. Shames, 2015 .

Safety, efficacy, and pharmacodynamics of the investigational agent orteronel (TAK-700) in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study.

M. Gross, J. Hainsworth, L. Hart, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase (Ph) I/II Study of CR011-VcMMAE, an Antibody-Drug Conjugate, in Patients (Pts) with Locally Advanced or Metastatic Breast Cancer (MBC).

L. Hart, J. Bendell, P. Siegel, 2009 .

Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)

A. Bardia, H. Rugo, A. DeMichele, 2021, Clinical Cancer Research.

A phase 2 study of BIND-014 (PSMA-targeted docetaxel nanoparticle) administered to patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).

H. Scher, M. Milowsky, L. Hart, 2016 .

Abstract 5514: Pharmacokinetics of BIND-014 (docetaxel nanoparticles for injectable suspension) in preclinical species and patients with advanced solid tumors

P. LoRusso, L. Hart, H. Burris, 2015 .

Phase I/II Study of Panobinostat and Carfilzomib in Patients (pts) with Relapsed or Refractory Multiple Myeloma (MM), Interim Phase I Safety Analysis

I. Flinn, L. Hart, P. Murphy, 2012 .

First-line ribociclib (RIB) + letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses.

G. Hortobagyi, L. Hart, C. Arteaga, 2018 .

Abstract CT045: Ribociclib + letrozole for first-line treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers

G. Hortobagyi, F. André, M. Campone, 2017 .

Clinical management and resolution of stomatitis in BOLERO-2.

G. Hortobagyi, J. Baselga, H. Rugo, 2013 .

XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease

P. Neven, H. Rugo, L. Hart, 2023, Breast Cancer Research.

Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy

Trevor W. Heritage, L. Hart, J. Goldschmidt, 2023, Advances in therapy.

A phase II study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma.

Douglas B. Johnson, P. Ott, L. Hart, 2017 .

Abstract CT012: Open-label, multicenter, Phase Ib study to assess safety, tolerability and efficacy of adavosertib monotherapy in patients with advanced solid tumors: Expansion cohorts

Suzanne F. Jones, A. Tinker, A. Oza, 2019, Clinical Trials.

A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors

Suzanne F. Jones, A. Tinker, A. Oza, 2023, Targeted Oncology.

Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain.

L. Hart, M. Simmonds, R. Portenoy, 2001, Journal of pain and symptom management.

1530PDResults of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC)

C. Rudin, A. Chiang, T. Burns, 2017 .

A single-arm, open-label, multicenter phase I/II study of the combination of panobinostat (pan) and carfilzomib (cfz) in patients (pts) with relapsed/refractory multiple myeloma (RR MM).

L. Hart, V. Gian, P. Murphy, 2012 .

Efficacy and safety of ribociclib (LEE011) + letrozole in elderly patients with hormone receptor-positive (HR+), HER2-negative (HER2−) advanced breast cancer (ABC) in MONALEESA-2

M. Campone, L. Hart, H. Burris, 2017 .

Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.

F. Saad, J. Nelson, H. Scher, 2015, The Lancet. Oncology.

Impact of ribociclib (RIB) dose modifications (mod) on overall survival (OS) in patients (pts) with HR+/HER2- advanced breast cancer (ABC) in MONALEESA(ML)-2.

P. Neven, A. Bardia, L. Hart, 2022, Journal of Clinical Oncology.

A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer

E. Winer, Zhou Zhu, P. Morris, 2020, Clinical Cancer Research.

mTOR inhibitor everolimus (Ev) and IGFR inhibitor OSI-906 (OSI) for the treatment of patients (pts) with refractory metastatic colorectal cancer (mCRC): A Sarah Cannon Research Institute phase I trial.

L. Hart, J. Bendell, H. Burris, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.